ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
ArriVent BioPharma has entered a collaboration with Jiangsu Alphamab Biopharmaceuticals to develop and commercialize novel antibody drug conjugates (ADCs) for cancer treatment. Under the agreement, ArriVent will utilize Alphamab's ADC research platform, while Alphamab will leverage ArriVent's global development expertise. The agreement includes potential milestone and upfront payments to Alphamab worth up to $615.5 million, excluding Greater China where Alphamab retains development and commercialization rights. Alphamab will also receive tiered sales royalties from ArriVent for each ADC product.
- Collaboration with Alphamab to enhance ADC research and development capabilities.
- Potential milestone and upfront payments to Alphamab worth up to $615.5 million.
- ArriVent gains exclusive global development and commercialization rights, excluding Greater China.
- Potential addition of multiple innovative ADC programs to ArriVent's pipeline.
- Alphamab to receive tiered sales royalties from ArriVent for each ADC product.
- rights for ArriVent in Greater China, where Alphamab retains development and commercialization rights.
- High upfront and milestone payments up to $615.5 million may impact ArriVent's financials.
Insights
The collaboration between ArriVent and Alphamab signifies a substantial financial commitment with potential upfront and milestone payments amounting to
The focus on ADCs (antibody drug conjugates) in this collaboration is of particular interest in the oncology field. ADCs are a promising class of therapeutics that combine the targeting capability of antibodies with the cancer-killing ability of chemotherapy drugs. Alphamab's proprietary glycan-conjugation and linker-payload technologies suggest a sophisticated approach to enhancing the efficacy and specificity of these treatments. This could potentially lead to breakthrough therapies that address unmet needs in cancer treatment. For stakeholders, the clinical success of these programs could translate into significant advances in patient care and substantial market opportunities.
From a market perspective, the collaboration between ArriVent and Alphamab positions both companies to tap into the rapidly growing market for ADCs. The global ADC market is anticipated to expand significantly due to the increasing prevalence of cancer and the demand for more effective and targeted therapies. ArriVent's global development and commercialization rights, excluding greater China, enable it to penetrate multiple regional markets, which can result in a diversified revenue stream. However, investors should be cautious about the competitive landscape, as several other biopharmaceutical companies are also advancing ADC programs. Continuous innovation and successful clinical outcomes will be critical to maintaining a competitive edge.
Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise
Upfront and milestone payments to Alphamab worth up to
SUZHOU, China and NEWTOWN SQUARE, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., (“ArriVent”) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the Company has entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly owned subsidiary of Alphamab Oncology, to discover, develop and commercialize novel antibody drug conjugates (“ADCs”) for the treatment of cancers.
“This exciting collaboration strengthens and complements our pipeline with the potential to add multiple innovative new ADC programs and exemplifies our strategic model of identifying and developing potential first-and best-in-class product candidates from across the globe,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent. “We look forward to complementing the research and discovery capabilities of Alphamab with our global drug development and commercialization expertise to address the unmet needs of cancer patients.”
“ArriVent shares our passion for developing differentiated, clinically valuable, and globally competitive new drugs,” said Ting Xu, Ph.D., Founder, Chairman, and CEO of Alphamab Oncology. “This collaboration, based on Alphamab’s proprietary and clinically validated glycan-conjugation platform, combined with ArriVent’s deep knowledge in oncology and extensive development experience, provides us with the opportunity to work together to deliver important new oncology therapeutics to patients.”
Under the agreement, both companies will leverage Alphamab’s proprietary linker-payload platform and glycan-conjugation technology to identify novel ADCs for oncology indications. The agreement gives ArriVent exclusive rights to develop and commercialize ADCs globally, except greater China, which includes outside of mainland China, Hong Kong, Macau and Taiwan where Alphamab retains the right to develop and commercialize the ADCs.
The terms of the agreement include combined upfront and potential milestone payments to Alphamab of up to
About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
About Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. The Alphamab Oncology’s highly differentiated inhouse pipeline consists of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates in staggered development status in oncology, including, among others, one approved for marketing by the National Medical Products Administration of China and three in late clinical stage. Alphamab Oncology has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, Alphamab Oncology is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding ArriVent’s ability to discover develop, and commercialize ADCs in collaboration with Alphamab, the potential milestone payments and tiered sales royalty payments to Alphamab, if any, the potential for such ADCs to help to address the unmet needs of cancer patients, the timing, progress and results of pre-clinical studies and clinical trials for any such ADCs, including our product development plans and strategies, ArriVent’s clinical programs, future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in ArriVent’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on March 28, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.
Contact for Investors & Media:
Argot Partners
212.600.1902
ArriVent@argotpartners.com
FAQ
What is the collaboration between ArriVent and Alphamab about?
How much are the upfront and milestone payments in the ArriVent and Alphamab collaboration?
What rights does ArriVent have under the collaboration agreement with Alphamab?
What is Alphamab’s role in the collaboration with ArriVent?
Will Alphamab receive any royalties from ArriVent?
When was the collaboration between ArriVent and Alphamab announced?
What is the stock symbol for ArriVent?
